It has been proposed that this upregulation of RAD51 may be a result of the high proliferative index of tumour cells, and it has been shown that lowering RAD51 expression or activity (through inhibition) can sensitise cancer cells to chemotherapeutics (such as cisplatin, doxorubicin or IR) [253]. Here, RAD51 is linked to cancer.